PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsExenatide
Byetta(exenatide)
Bydureon, Byetta, Exenatide Synthetic (exenatide) is a protein pharmaceutical. Exenatide was first approved as Byetta on 2005-04-28. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Exenatide synthetic (discontinued: Bydureon, Byetta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Exenatide synthetic
Tradename
Company
Number
Date
Products
BYDUREONAstraZenecaN-022200 DISCN2012-01-27
1 products, RLD
BYDUREON PENAstraZenecaN-022200 DISCN2014-02-28
1 products, RLD
BYETTAAstraZenecaN-021773 DISCN2005-04-28
2 products, RLD
BYDUREON BCISEAstraZenecaN-209210 DISCN2017-10-20
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bydureon bciseNew Drug Application2025-05-28
byettaNew Drug Application2025-09-02
exenatideANDA2025-08-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
EXENATIDE SYNTHETIC, BYDUREON, ASTRAZENECA AB
2025-01-22PED
2024-07-22NPP
EXENATIDE SYNTHETIC, BYDUREON BCISE, ASTRAZENECA AB
2025-01-22PED
2024-07-22NPP
EXENATIDE SYNTHETIC, BYDUREON PEN, ASTRAZENECA AB
2025-01-22PED
2024-07-22NPP
EXENATIDE SYNTHETIC, BYETTA, ASTRAZENECA AB
2024-11-04M-232
Patent Expiration
Patent
Expires
Flag
FDA Information
Exenatide Synthetic, Bydureon Bcise, Astrazeneca Ab
88950332030-10-04DPU-2589, U-2590, U-2597, U-2601, U-2602, U-3188, U-3189, U-3190
Exenatide Synthetic, Bydureon, Astrazeneca Ab
83619722028-03-21U-2588
85016982027-06-20DPU-2588
83296482026-08-18U-2588, U-2589, U-2590, U-2593, U-2594, U-2595, U-2596, U-3188, U-3189, U-3190
89068512026-08-18U-2588, U-2589, U-2590, U-2593, U-2597, U-3188, U-3189, U-3190
98840922026-08-18U-2588, U-2589, U-2590, U-2593, U-2594, U-2595, U-2596, U-2597, U-3188, U-3189, U-3190
65151172025-10-04DS, DPU-2588
74562542025-06-30DPU-2588, U-2589, U-2590, U-3188, U-3189, U-3190
76121762025-04-13DPU-2588, U-2589, U-2590, U-3188, U-3189, U-3190
84316852025-04-13DPU-2588, U-2589, U-2590, U-2597, U-3188, U-3189, U-3190
84611052025-04-13DPU-2588, U-2589, U-2590, U-2597, U-3188, U-3189, U-3190
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ01: Exenatide
HCPCS
No data
Clinical
Clinical Trials
380 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E112525695351217
Diabetes mellitusD003920EFO_0000400E08-E131322442625126
ObesityD009765EFO_0001073E66.95101012843
Type 1 diabetes mellitusD003922EFO_0001359E106934321
Healthy volunteers/patients———7——3515
Insulin resistanceD007333EFO_0002614E88.81923—5313
Glucose intoleranceD018149HP_0000833R73.0322—9113
OverweightD050177—E66.34324—11
HypoglycemiaD007003—E16.23421310
Weight lossD015431——133129
Show 40 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20151——7
Morbid obesityD009767EFO_0001074——31—14
SyndromeD013577——111—13
CraniopharyngiomaD003397——121——3
Sexual infantilismD050035——111—13
Body weightD001835EFO_0004338——11—13
Cognitive dysfunctionD060825—G31.84—11——2
Left ventricular dysfunctionD018487————2——2
Myocardial ischemiaD017202EFO_1001375I20-I25——1——1
Chronic renal insufficiencyD051436—N18——1——1
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InsulinomaD007340——51——38
Congenital hyperinsulinismD044903——31——25
HyperinsulinismD006946—E16.111——45
NesidioblastosisD046768EFO_0007318E16.921——24
AlcoholismD000437EFO_0003829F10.121———3
Ischemic strokeD000083242———3———3
StrokeD020521EFO_0000712I63.9—2——13
Smoking cessationD016540EFO_0004319—22———3
Cocaine-related disordersD019970—F1431———3
Addictive behaviorD016739EFO_0004347—11———2
Show 14 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437—N192———13
Glucose metabolism disordersD044882——1———12
Alcohol drinkingD000428EFO_0004329—1————1
Metabolic diseasesD008659EFO_0000589E88.91————1
Endocrine system diseasesD004700EFO_0001379E34.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PancreatitisD010195EFO_0000278K85————22
Pancreatic neoplasmsD010190EFO_0003860C25————22
Prader-willi syndromeD011218Orphanet_739Q87.11————22
CarcinomaD002277—C80.0————11
Thyroid neoplasmsD013964EFO_0003841—————11
Neuroendocrine carcinomaD018278——————11
Papillary thyroid cancerD000077273——————11
Thyroid diseasesD013959—E00-E07————11
Coronary diseaseD003327——————11
Aortic valve diseaseD000082862——————11
Show 17 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameExenatide
INNexenatide
Description
EXENATIDE
Classification
Protein
Drug classpeptides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
Identifiers
PDB—
CAS-ID141758-74-9
RxCUI—
ChEMBL IDCHEMBL414357
ChEBI ID—
PubChem CID16157882
DrugBankDB01276
UNII ID9P1872D4OL (ChemIDplus, GSRS)
Target
Agency Approved
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Byetta – Amylin Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Byetta – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Byetta – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Exenatide – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bydureon – Alkermes
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bydureon – AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Bydureon – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Exenatide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 18,684 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bydureon bcise
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
85,873 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use